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Abstract
In studies that use DNA arrays to assess changes in gene expression, it is preferable to measure
the significance of treatment effects on a group of genes from a pathway or functional category such
as gene ontology terms (GO terms, http://www.geneontology.org) because this facilitates the
interpretation of effects and may markedly increase significance. A modified meta-analysis method
to combine p-values was developed to measure the significance of an overall treatment effect on
such functionally-defined groups of genes, taking into account the correlation structure among
genes. For hypothesis testing that allows gene expression to change in both directions, p-values are
calculated under the null distribution generated by a Monte Carlo method.
As a test of this procedure, we attempted to distinguish altered pathways in microarray studies
performed with Mitochips, oligonucleotide microarrays specific to mitochondrial DNA-encoded
transcripts. We found that our analytic method improves the specificity of selection for altered
pathways, due to incorporation of the inter-gene correlation structure in each pathway. It is thus
a practical method to measure treatment effects on GO groups. In many actual applications,
microarray experiments measure treatment effects under complicated design structures and with
small sample sizes. For such applications to real data of limited statistical power, and also in
computer simulations, we demonstrate that our method gives reasonable test results.
Introduction
The advent of DNA microarray technology has revolution-
ized genomic research and medicine because of its ability
to simultaneously determine the expression levels of
thousands of genes. However, the interpretation of large
amounts of microarray gene expression data, and the abil-
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ity to derive biologically meaningful conclusions from
such data, have always been daunting tasks for statisti-
cians. Because of the high volume and complex character-
istics of microarray data, much of the initial work on their
analysis has focused on development of data mining or
data reduction methods to identify differentially
expressed genes. Typically, the p-value of a test statistic is
calculated for each gene, the genes are ranked according to
these p-values, and a pre-specified significance criterion,
such as the false discovery rate, is used to determine a cut-
off which creates a category of differentially expressed
genes [1-3].
Attempts to interpret individual genes in a list of signifi-
cant genes are demanding and laborious. Therefore,
recent efforts have focused on discovery of biological
pathways rather than on individual gene function. Gene
ontology terms (GO terms, http://www.geneontol
ogy.org) reflect gene groupings based on molecular func-
tion, biological process, or cellular structure/organelle.
The interpretation of differentially expressed GO groups is
generally simpler than the presentation of a list of statisti-
cally significant genes, and more resistant to erroneous
conclusions that can arise from microarray artefacts.
Several statistical methods that combine the analysis of
differential gene expression with biological databases
have been proposed and implemented in computer pack-
ages for a more rapid interpretation of genome-wide
expression data [4]. However, most such methods are
based on a series of univariate statistical tests and do not
properly account for the complex structure of gene inter-
actions. The statistical significance of a GO group is com-
monly assessed by comparing the number of statistically
significant genes in the group to the number expected by
chance using Fisher's exact test, which is based on the
hypergeometric distribution [5]. Fisher's exact test is used
to compare these proportions to assess overrepresentation
of significant genes in functional categories. This
approach is not amenable to correction for correlations
among  p-values, since the test inherently assumes
exchangeability among genes, an assumption which is not
valid under arbitrary or actual correlation structures [6,7].
Hotelling's T2 Statistic and permutation methods address
the correlation structure among genes. Hotelling's T2 sta-
tistic is not applicable when the sample size is smaller
than the number of genes in a GO term [8]. Permutation
methods, although quite valuable under appropriate con-
ditions, are severely compromised by limited numbers of
permutable sample pairs. In many cases, the design of
microarray studies has a rather complicated structure
intended to manage technical variation associated with
differences among probes, dyes, and reagent batches by
creating treatment blocks within these sources of variation
[9]. Such cases are not suited to permutation methods.
A modified meta-analysis method was developed by
Delongchamp et al. [10] to combine p-values, and thus to
measure the significance of an overall treatment effect on
a group of genes, while taking into account the inter-genic
correlation structure. The method is based on the fact that
p-values follow a uniform distribution under the null
hypothesis. Inverse-normal transformed p-values have a
normal distribution and their sum over a set of genes also
would follow a normal distribution, provided that the
component p-values are independent. The test we have
developed to measure the significance of overall treat-
ment effect on genes within a GO category is based on a
modification of this statistic, to reflect the actual correla-
tion structure among genes sharing a GO term.
In this paper, we extend the method from a simple one-
class t-test with the null hypothesis H0 : μ = 0 to a test for
pair-wise contrast in a fixed-effects linear model. In the
following sections, we describe in detail the extension of
the methodology, with validation through computer sim-
ulations and application to two toxicogenomics studies
designed to evaluate treatment effects on the levels of
mRNA transcripts involved in mitochondrial function.
We thus demonstrate that this methodology provides a
practical approach to testing the significance of the treat-
ment effects on gene classes defined by GO terms, and by
extension on any other prior categorization of genes into
functional subsets. Because many microarray experiments
measure treatment effects under complicated design struc-
tures and with small sample sizes [9], we used a simula-
tion study to determine whether the method gives
reasonable results under these conditions.
Specific applications to toxicogenomics studies showed
that the methodology has improved specificity in choos-
ing significantly altered pathways or functional categories,
and may thus assist in the understanding of molecular
mechanisms of mitochondrial toxicity in the liver induced
by anti-HIV drugs [11,12] and in assessing effects on mito-
chondrial function of weight-reducing dietary supple-
ments, such as usnic acid [13].
Methods
Measurement of a treatment effect for each gene
Under a fixed-effects linear model, gene expression data
for an arbitrary gene can be written as y = Xβ + ε, where y
and ε are n × 1 random vectors, X is a known n × p design
matrix of rank r, and β  is a p  × 1 vector representing
unknown parameters. The vector y denotes an observed
measurement of expression, suitably transformed, for n
biological samples, and ε is an error vector, distributed as
Nn (0, σ2 In), where σ2 denotes the unknown within-treat-BMC Bioinformatics 2008, 9(Suppl 9):S20 http://www.biomedcentral.com/1471-2105/9/S9/S20
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ment variance among samples. The parameters β and σ2
are assumed to be gene-specific. Statistical analyses are
applied to one gene at a time, with a common design
matrix, X. The unbiased estimators of β and σ2 are
In many toxicogenomic studies, the significance of a treat-
ment effect is tested under the null hypothesis H0 : cβ = 0,
where cβ is a pair-wise contrast among treatments. Under
the null hypothesis,   has a t-distribution
with n - r degrees of freedom, and the p-value to assess the
significance of a treatment is calculated from this statistic.
Test for a gene group
A modified meta-analysis method of combining p-values
was developed to measure the significance of an overall
treatment effect on any group of genes by a one-class t-test
[10]. The p-value calculated from the null hypothesis is a
random variable with uniform distribution, which can be
transformed to a suitable probability distribution.
Inverse-normal transformed p-values,  zk  =  Φ-1 (1 - pk)
~N(0, 1), k = 1, , m have a normal distribution and their
sum,  , is also normally distributed
when p-values are independent. Here, pk represents a p-
value for a gene in a GO group comprising m genes. The
p-value for the sum of inverse-transformed p-values,
, gives the overall significance of
the treatment effect on the GO group. We refer to this as
the naïve estimate because it assumes independence
among p-values.
In reality, genes in a GO group are likely to be functionally
related and thus not independent. When the correlation
structure among genes is known, we can make a simple
adjustment of the naïve estimate. In this case, the test sta-
tistics T still has a standard normal distribution and we
denote it as  , for the k-th gene in a GO
group. A common contrast vector, c, is used through all
genes since we are measuring same contrast for each gene.
The summary statistic for a GO group,
 is also nor-
mally distributed and its variance is
, where 1 is
m vector of 1s and R is the correlation matrix of (y1, y2, ,
ym). Note that
where rs,t is the s-th row and t-th column element of R.
Therefore,   is the appropriate p-value
which corrects the naïve p-value, .
It follows that  , where   is
the average of off-diagonal elements of R. The correction
depends only on the average correlation,  , and the cor-
rection tends to give a reduced significance when   > 0.
When  R  is unknown, we estimated the covariance,
 to provide an average
correlation coefficient   for the correction.
The correlation structure of p-values is different for a two-
sided t-test, which allows gene expression changes in both
directions, than for a one-sided situation. A two-tailed
test, in which p = 2(1 - Φ(|z|)), requires a different correc-
tion method, since the correlation among |zk|, k = 1, , m
differs from a one-sided test in which p = 1 - Φ(z). The null
distribution of the summary statistics 1'|z| can be gener-
ated through Monte Carlo sampling from the null distri-
bution of z, MVN(0, cov(z)). When z1, , zn are random
samples from MVN(0, cov(z)), the p-value for the
observed value, Ψ = 1'|z|, is computed as
, where I(A) is an indicator func-
tion which gives 1 if A is true, or 0 otherwise. Here, cov(z)
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has to be estimated from the data. The estimated correla-
tion,   and its variation,  , which has   for off-diago-
nal elements, are used to estimate cov(z).
Results
Simulation
The derivation of the method presented in the previous
section is based on the known correlation matrix of the
vector of dependent variable Y. When the correlation
matrix is not known, we use an estimate of the correlation
matrix. In reality, the correlation matrix is always
unknown. The proposed method produces an approxi-
mately correct p-value for a group of genes. To demon-
strate that the method gives not perfect but acceptably
correct p-values, we present simulation results in this sec-
tion. The validation is done by checking the cumulative
distribution of p-values from the proposed methods
under the null distribution. The p-values must have a uni-
form distribution, which should form a diagonal line in
the following figures if p-values are correctly calculated.
The simulation is conducted under a fairly common set of
conditions for microarray studies, comprising three treat-
ments with three samples (arrays) per treatment. Samples
are generated from N(μi, Σ) for each treatment, i = 1, 2 3,.
In this simulation, samples for two treatment have the
same average values, μ1 = μ2 = 1, and samples for the other
treatment have twice that average value μ3 = 2. P-values for
the pair-wise contrast are calculated under the null hypo-
thesis, H0 : μ1 = μ2. A GO term is composed of m = 20
genes which have correlation structure generated ran-
domly between 0.36 and 0.55. The standard deviations,
σi, i = 1, ,m for the genes, which are the diagonal ele-
ments of Σ, are generated randomly between 0.01 and
0.25. We iterated this procedure at least 10,000 times to
observe the distribution of calculated p-values.
Figure 1 plots the cumulative distribution of p-values from
a one-sided test when the number of samples is n = 9, i.e.,
3 groups with 3 samples for each group. The naïve p-val-
ues, shown by the red line, clearly deviate from the diago-
nal line. Almost 30% of p-values are estimated to be less
ˆ R R r
Cumulative distribution of p-values for one-sided test case with sample size n = 9 Figure 1
Cumulative distribution of p-values for one-sided test case with sample size n = 9. The naïve p-values (dashed red 
line) deviate from the diagonal line. Almost 30% of p-values are estimated to be less than 0.05. The corrected p-values (dashed 
blue line) fall very near the diagonal line.BMC Bioinformatics 2008, 9(Suppl 9):S20 http://www.biomedcentral.com/1471-2105/9/S9/S20
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than 0.05, indicating that the naïve p-values lead to a very
high false-discovery rate. The corrected p-values (dashed
blue line) fall very near the diagonal line. The corrected p-
values thus have more specificity in choosing altered func-
tional gene groups than the naïve p-values.
Figure 2 shows the simulation result for a two-sided case.
P-values are calculated from the null distribution gener-
ated from Monte Carlo samples from MVN(0, cov(z)).
Two estimates of cov(z) are used for the sampling. When
 is used, the empirical distribution of p-values is closer
to a uniform distribution than when   is used. The esti-
mate of the average correlation,  , is more robust than
that of each element of   when sample size is small (n =
3 for each group).
Figure 3 shows the distribution of p-values for a case with
larger samples. The simulation for one-class t-test with
sample size n = 25 was conducted as above, to compare
several methods for two sided tests. The empirical distri-
butions of p-values were generated from 500,000 itera-
tions. We looked at small p-values between 0.1 and 0.001
on a log scale. Figure 3 shows that the Hotelling T2 test
gives the smallest difference from the uniform distribu-
tion. The Hotelling T2 test is applicable when the number
of sample is larger than the number of genes in a group.
When we have a reasonably correct estimate of R, the 
method is a little better than the   method which uses an
approximation of R. Both the   method and the 
method give quite accurate p-values with reference to the
p-values from the true correlation matrix, R.
Examples
We present two real-world examples based on data from
Mitochip, a mitochondria-specific mouse oligonucleotide
microarray which was developed by Dr. Varsha Desai at
R
ˆ R
r
ˆ R
ˆ R
R
ˆ R R
Cumulative distribution of p-values for two-sided test case with sample size n = 9 Figure 2
Cumulative distribution of p-values for two-sided test case with sample size n = 9. P-values calculated from random 
samples based on   (dashed blue line) and   (dashed green line) give reliable corrections, while the naïve p-value (dashed 
red line) overstates the significance of the test.
R ˆ RBMC Bioinformatics 2008, 9(Suppl 9):S20 http://www.biomedcentral.com/1471-2105/9/S9/S20
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the National Center for Toxicological Research [11]. Mito-
chip measures the levels of mRNA for 542 mitochondrial
and nuclear genes associated with mitochondrial structure
and function. Each Mitochip includes 9 housekeeping
genes and 9 Arabidopsis plant genes to serve as positive and
negative control genes, respectively. We considered 317
relevant GO groups related to mitochondrial functions,
based on a database from Mouse Genome Informatics
(MGI, http://www.informatics.jax.org).
Table 1 shows the design of an experiment to test the
effects of zidovudine (AZT) and lamivudine (3TC) on
mouse-liver gene expression. AZT is an anti-HIV drug used
to reduce mother-to-child transmission of the virus. AZT
Comparison of two-sided tests with sample size n = 25 Figure 3
Comparison of two-sided tests with sample size n = 25. Hotelling T2 test (dashed blue line) gives the smallest difference 
from the uniform distribution. When we have enough number of samples to have a reasonably correct estimate of R, the   
method (dashed red line) is a little better than the   method (dashed green line). Both the   method and the   method 
give quite accurate p-values compared to the p-values from the true correlation matrix, R (dashed cyan line).
ˆ R
R ˆ R R
Table 1: Experimental design for the AZT and 3TC effects on mouse-liver gene expression.
Genotype (+/-) (+/+)
Treatment Vehicle AZT 240 mg/kg/d AZT+3TC 160+100 mg/kg/d Vehicle AZT+3TC 160+100 mg/kg/d
Batch 1 A1 B1 C1 D1 E1
Batch 2 A2 B2 C2 D2 E2
Batch 3 A3 B3 C3 D3 E3
Fifteen samples are collected and assayed for gene expression using the experimental designBMC Bioinformatics 2008, 9(Suppl 9):S20 http://www.biomedcentral.com/1471-2105/9/S9/S20
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is reported to produce severe adverse effects, and shows
more toxicity when AZT is applied in combination with
3TC. Adverse effects are believed to be due to drug-
induced mitochondrial disfunction [14].
Oxidative phosphorylation is a key mitochondrial func-
tion that requires the electron transport assembly of four
protein complexes (I, II, III, IV) to catalyze sequential oxi-
dation/reduction reactions, and complex V to generate
ATP. Several clinical and animal studies have investigated
the effect of nucleoside reverse transcriptase inhibitors
(NRTIs), analogs such as AZT, on mitochondrial respira-
tory chain complexes. These studies suggest that there is a
deficit in one of the components of complexes I and IV in
skeletal muscle of children perinatally exposed to antiret-
roviral nucleoside analogues [15].
Table 2 shows p-values indicating the significance of treat-
ment effects on the GO groups related to oxidative phos-
phorylation and apoptosis. The two-sided correction
method detects significant effects on genes encoding com-
ponents of complexes III and IV, whereas the naïve
method finds that genes in all 5 complexes are signifi-
cantly affected. This demonstrates that the two-sided cor-
rection method is more specific in finding significantly
affected gene groups, although of course the "true" answer
is not known a priori. Although Fisher's exact test also
detects significant alteration in genes of complex IV, this
test appears to be detecting a gene group that is different
from the other groups, rather than registering treatment
effects directly. The one-sided test is not applicable since
it seems that gene expression changes in both directions
after AZT and 3TC treatment.
Usnic acid is a lichen metabolite used as a weight-loss die-
tary supplement due to its uncoupling action on mito-
chondria. However, its use has been associated with
severe liver disorders in many individuals. Animal studies
conducted thus far have evaluated effect of usnic acid on
mitochondria, primarily by measuring the rate of oxygen
consumption and/or ATP generation. Generation of ATP
requires tight coupling of electron transport with oxida-
tive phosphorylation, maintained through a proton gradi-
ent across the inner mitochondrial membrane. An
important finding of the study is a lack of usnic acid effect
on complex V, despite a significant up-regulation of all
four complexes of the electron transport chain. Usnic acid
is a known uncoupler that is highly lipophilic in both
neutral and anionic forms due to its numerous carbonyl
groups that absorb the negative charge of the anion by res-
onance stabilization. This lipophilicity of usnic acid and
the usniate anion allows easy passage of both entities
through the mitochondrial membranes by passive diffu-
sion into the matrix where it is ionized, releasing a proton
into the matrix. The resulting usniate anion can then dif-
fuse back into the inter-membrane space where it binds to
the proton on the acidic side of the inner membrane to re-
form usnic acid which can then diffuse back into the
matrix. The resulting cycle causes proton leakage that
eventually can dissipate the proton gradient across the
inner membrane, disrupting the tight coupling between
electron transport and ATP synthesis. This model would
explain the absence of gene-expression changes associated
with complex V in usnic acid-treated mice, despite the
increased electron transport by complexes I – IV. It may
also explain the decline in ATP level in spite of increased
oxygen consumption.
In Table 3, only the two-sided correction method enables
us to explain the function of usnic acid as described
above. The one-sided correction method gives p-values
similar to those in the two-sided correction method, but
this is likely to be due to most of the gene expression
changes entailing up-regulation. When the direction of
gene expression change due to a treatment is known, then
the one-sided correction method is the appropriate
choice; it also needs less computation time than the two-
sided correction method which employs Monte Carlo
sample generation.
Discussion
In many studies that use microarray data, the number of
samples is small as in the first example shown above.
While the number of samples in the simulations is only 3
for each group, the distribution of corrected p-values
Table 2: Effects of AZT and 3TC on oxidative phosphorylation and apoptosis.
gene group # genes up # P<0.05 Fisher's exact Not corrected One-sided correction Two-sided correction
Complex1 29 18 10 0.460 7.41E-6 0.600 0.049
Complex2 3 2 1 0.688 0.017 0.828 0.043
Complex3 7 5 3 0.401 5.3E-5 0.559 0.002
Complex4 13 8 8 0.026 1.25E-07 0.641 0.001
Complex5 14 6 6 0.273 0.0003 0.982 0.022
apoptosis 18 10 7 0.347 2.92E-5 0.592 0.005
P-values calculated from four methods are presented for a comparison. The number of genes, up-regulated genes, and significantly expressed genes 
in each gene group are presentedBMC Bioinformatics 2008, 9(Suppl 9):S20 http://www.biomedcentral.com/1471-2105/9/S9/S20
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approximates a uniform distribution. The estimation for
the correlation,  , might not be very close to the true cor-
relation, R. However, the correction methods that depend
only on the average correlation,  , are more robust
because the estimation of   is more robust.
For the one-sided test, the correction for the correlation
depends only on  , the average of off-diagonal elements
of the correlation matrix. The corrections using   or 
are equivalent for the one-sided test method. Important
points in choosing a correlation estimate for the two-
sided test are the following; 1) The correlation estimate
should be robust for small sample sizes, and 2) The corre-
lation estimate should preserve  .   satisfies these two
conditions.
When the direction of gene expression change is pre-spec-
ified, the one-sided test is a good choice since it is easy and
fast to calculate p-values. However, the two-sided test is
the one we have to use in most cases, because it is usually
not possible to pre-specify how individual genes will
respond to treatment in the exploratory context. When we
have a small number of samples to estimate the correla-
tion, the   method gives a robust result. Since   misrep-
resents the true correlation, and gives biased p-values, the
 method works better for larger sample sizes. This is
seen in Figure 3, where the   method is better than the
 method. We hesitate to present a specific threshold
sample size as sufficient for a converged correlation esti-
mate, since it varies with respect to several conditions,
such as the number of genes in a group, the variation of
the elements of the correlation matrix, etc. The simulation
result in Figure 3 shows that both methods give quite
accurate p-values compared to the p-values from the true
correlation matrix, R. The Hotelling T2 test is the best
choice whenever it is applicable.
In Table 1, the distribution of animals from different treat-
ment groups (A-E) in three batches (1–3) gives no per-
mutable pairs. In this case, randomization methods are
not applicable. Even though randomization methods
inherently take into account the correlation structure
among genes, they may not be practical when the design
of the experiment is complicated and the number of sam-
ples per group is small, reducing the numbers of permut-
able pairs.
Randomization methods that permute class labels can
adjust p-values for the correlation structure among genes.
Randomization methods choose a summary statistic (e.g.
enrichment score (ES) in [16], average z-score in [17]),
which reflects the degree to which a set of genes is
enriched. When the significance of the summary statistic
is measured by permuting class labels, the method pre-
serves gene-gene correlations and when applicable, would
give similar result to the presented method. Randomiza-
tion methods that permute gene labels, such as Fisher's
exact test, do not preserve the correlation structure and
misrepresent the group's significance.
Conclusion
We have presented a method to test the significance of
expression changes within a group of genes, while consid-
ering the correlation structure among genes in each group.
This method will enable the rapid detection of microarray
evidence indicating altered cell functions or pathways,
and will facilitate the interpretation of microarray out-
comes. Application of the method to real data shows that
it is an improved, practical method to evaluate the effects
of treatments on functional classes of genes such as those
based on Gene Ontology descriptors.
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